Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma

被引：81

作者：

Ohtsuka, Mikio ^{[1
]}

Miura, Takako ^{[1
]}

Mori, Tatsuhiko ^{[1
]}

Ishikawa, Masato ^{[1
]}

Yamamoto, Toshiyuki ^{[1
]}

机构：

[1] Fukushima Med Univ, Sch Med, Dept Dermatol, Fukushima 9601295, Japan

来源：

JAMA DERMATOLOGY | 2015年 / 151卷 / 07期

关键词：

CANCER;

D O I：

10.1001/jamadermatol.2015.0249

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100227 [皮肤病学];

摘要：

[No abstract available]

引用

收藏

页码：797 / 799

页数：4

相关论文

共 6 条

[1]

Paradoxical Reactions to Targeted Biological Treatments: A Way to Treat and Trigger? [J].

Brunasso, Alexandra M. G. ;

Laimer, Martin ;

Massone, Cesare .

ACTA DERMATO-VENEREOLOGICA, 2010, 90 (02) :183-185

[2]

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy [J].

Dolan, Dawn E. ;

Gupta, Shilpa .

CANCER CONTROL, 2014, 21 (03) :231-237

[3]

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer [J].

Dulos, John ;

Carven, Gregory J. ;

van Boxtel, Susan J. ;

Evers, Sabine ;

Driessen-Engels, Lilian J. A. ;

Hobo, Willemijn ;

Gorecka, Monika A. ;

de Haan, Anton F. J. ;

Mulders, Peter ;

Punt, Cornelis J. A. ;

Jacobs, Joannes F. M. ;

Schalken, Jack A. ;

Oosterwijk, Egbert ;

van Eenennaam, Hans ;

Boots, Annemieke M. .

JOURNAL OF IMMUNOTHERAPY, 2012, 35 (02) :169-178

[4]

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial [J].

Robert, Caroline ;

Ribas, Antoni ;

Wolchok, Jedd D. ;

Hodi, F. Stephen ;

Hamid, Omid ;

Kefford, Richard ;

Weber, Jeffrey S. ;

Joshua, Anthony M. ;

Hwu, Wen-Jen ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Dronca, Roxana ;

Zarour, Hassane ;

Joseph, Richard W. ;

Boasberg, Peter ;

Chmielowski, Bartosz ;

Mateus, Christine ;

Postow, Michael A. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Li, Xiaoyun Nicole ;

Iannone, Robert ;

Ebbinghaus, Scot W. ;

Kang, S. Peter ;

Daud, Adil .

LANCET, 2014, 384 (9948) :1109-1117

[5]

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma [J].

Samaik, Amod A. ;

Yu, Bin ;

Yu, Daohai ;

Morelli, Dawn ;

Hall, MacLean ;

Bogle, Dilip ;

Yan, Lulu ;

Targan, Stephan ;

Solomon, Jolie ;

Nichol, Geoff ;

Yellin, Michael ;

Weber, Jeffrey S. .

CLINICAL CANCER RESEARCH, 2011, 17 (04) :896-906

[6]

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab [J].

Topalian, Suzanne L. ;

Sznol, Mario ;

McDermott, David F. ;

Kluger, Harriet M. ;

Carvajal, Richard D. ;

Sharfman, William H. ;

Brahmer, Julie R. ;

Lawrence, Donald P. ;

Atkins, Michael B. ;

Powderly, John D. ;

Leming, Philip D. ;

Lipson, Evan J. ;

Puzanov, Igor ;

Smith, David C. ;

Taube, Janis M. ;

Wigginton, Jon M. ;

Kollia, Georgia D. ;

Gupta, Ashok ;

Pardoll, Drew M. ;

Sosman, Jeffrey A. ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) :1020-+